TRUNCATE-TB

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis

Can a strategy of treating patients with drug-sensitive TB for 2 months with combinations which include new drugs or optimised doses of currently available drugs be as effective long term as standard treatment given for 6 months?

What is this study about?

The primary aim is to test the hypothesis that the TRUNCATE-TB management strategy is non-inferior to the standard TB management strategy assessed by the proportion of patients with unsatisfactory outcome at 2 years (96 weeks) after randomisation.

Type of study

Randomised trial

Contact details

truncate-tb@nus.edu.sg

Who is funding the study?

MRC/DfID/Wellcome.

When is it taking place?

TRUNCATE-TB was funded September 2013; first patient enrolled March 2018, funded for 5 years.

Where is it taking place?

South East Asia

Who is included?

Adult patients with drug-sensitive pulmonary TB confirmed by GeneXpert.